Avalo Therapeutics, Inc. short interest in 2023
In 2023, Avalo Therapeutics, Inc.'s disclosed short interest ran from 0.43% of shares outstanding on 13 Jan 2023 to 6.57% on 15 Dec 2023, a change of +6.14 percentage points. The year's high was 9.43% on 15 Nov 2023 and its low 0.14% on 31 Mar 2023, averaging 2.24% across 15 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.88 days on 13 Jan 2023. Full history: Avalo Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 0.43% (13 Jan 2023)
- End of year
- 6.57% (15 Dec 2023)
- Change
- +6.14 pp
- High
- 9.43% (15 Nov 2023)
- Low
- 0.14% (31 Mar 2023)
- Average
- 2.24%
- Highest days to cover
- 6.88 (13 Jan 2023)
- SEC filings marked
- 8
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 0.43% | 6.88 | |
| 31 Jan 2023 | 0.30% | 1.47 | |
| 15 Feb 2023 | 0.20% | 1.00 | |
| 28 Feb 2023 | 0.26% | 2.41 | |
| 15 Mar 2023 | 0.20% | 1.31 | |
| 31 Mar 2023 | 0.14% | 1.00 | 10-K filed, results (8-K) |
| 28 Apr 2023 | 0.28% | 1.14 | |
| 15 May 2023 | 0.33% | 1.62 | 10-Q filed, results (8-K) |
| 31 May 2023 | 0.32% | 1.00 | |
| 15 Jun 2023 | 0.29% | 1.00 | |
| 15 Aug 2023 | 4.73% | 1.00 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 4.74% | 1.00 | |
| 15 Nov 2023 | 9.43% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 5.31% | 1.00 | |
| 15 Dec 2023 | 6.57% | 1.00 |
See also: Avalo Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.